MBA MBE - PsyBio Therapeutics Chief Officer
| PSYBF Stock | USD 0.0001 0.00 0.00% |
Insider
MBA MBE is Chief Officer of PsyBio Therapeutics Corp
| Age | 56 |
| Phone | 513 449 9585 |
| Web | https://www.psybiolife.com |
PsyBio Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9829) % which means that it has lost $0.9829 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.0952) %, meaning that it generated substantial loss on money invested by shareholders. PsyBio Therapeutics' management efficiency ratios could be used to measure how well PsyBio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Sebastien Plouffe | Defence Therapeutics | 51 | |
| Simon Beaudoin | Defence Therapeutics | 39 | |
| Shachar CPA | Enlivex Therapeutics | 47 | |
| Sigal Arad | Enlivex Therapeutics | N/A | |
| Eric Tse | Sino Biopharmaceutical Ltd | 27 | |
| Moutih Rafei | Defence Therapeutics | 41 | |
| Oren Hershkovitz | Enlivex Therapeutics | 47 | |
| Pr MD | Enlivex Therapeutics | 68 | |
| Carrie Cesarone | Defence Therapeutics | 58 | |
Management Performance
| Return On Equity | -3.1 | |||
| Return On Asset | -0.98 |
PsyBio Therapeutics Corp Leadership Team
Elected by the shareholders, the PsyBio Therapeutics' board of directors comprises two types of representatives: PsyBio Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PsyBio. The board's role is to monitor PsyBio Therapeutics' management team and ensure that shareholders' interests are well served. PsyBio Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PsyBio Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Jones, Inventor Board | ||
| Ross Carmel, Chief Director | ||
| Noah Davis, S CFO | ||
| Evan Levine, CEO CoFounder | ||
| MBA MBE, Chief Officer |
PsyBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PsyBio Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.1 | |||
| Return On Asset | -0.98 | |||
| Current Valuation | 3.69 M | |||
| Shares Outstanding | 80.85 M | |||
| Shares Owned By Insiders | 25.61 % | |||
| Shares Owned By Institutions | 13.23 % | |||
| Price To Book | 202.42 X | |||
| Gross Profit | (1.56 M) | |||
| EBITDA | (10.91 M) | |||
| Net Income | (11.02 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in PsyBio Pink Sheet
PsyBio Therapeutics financial ratios help investors to determine whether PsyBio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PsyBio with respect to the benefits of owning PsyBio Therapeutics security.